Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (HB). Compounds may be administered to tissues including skin. Contemplated uses include treatment of disease, allergen immunotherapy, and immunization. Other aspects relate to compositions, methods and kits comprising heparin-binding peptides (HB) fused or conjugated to the therapeutic agents.

An improved method of deprotection in solid phase peptide synthesis is disclosed. In particular the deprotecting composition is added in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated acid from the preceding coupling cycle, and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle. Thereafter, the ambient pressure in the vessel is reduced with a vacuum pull to remove the deprotecting composition without any draining step and without otherwise adversely affecting the remaining materials in the vessel or causing problems in subsequent steps in the SPPS cycle.

An improved method of deprotection in solid phase peptide synthesis is disclosed. In particular the deprotecting composition is added in high concentration and small volume to the mixture of the coupling solution, the growing peptide chain, and any excess activated acid from the preceding coupling cycle, and without any draining step between the coupling step of the previous cycle and the addition of the deprotection composition for the successive cycle. Thereafter, the ambient pressure in the vessel is reduced with a vacuum pull to remove the deprotecting composition without any draining step and without otherwise adversely affecting the remaining materials in the vessel or causing problems in subsequent steps in the SPPS cycle.

Described herein is insulin, an insulin-like growth factor, parathyroid hormone, a fragment of parathyroid hormone, or a parathyroid hormone related protein that includes at least one bone targeting moiety, wherein the bone targeting moiety is covalently bonded to the peptide. Also described herein are the methods of making these compositions that prevent or treat conditions associated with bone loss and preventing bone fractures, and/or the inability to initiate de novo bone turnover and stimulate bone fracture repair.

Described herein is insulin, an insulin-like growth factor, parathyroid hormone, a fragment of parathyroid hormone, or a parathyroid hormone related protein that includes at least one bone targeting moiety, wherein the bone targeting moiety is covalently bonded to the peptide. Also described herein are the methods of making these compositions that prevent or treat conditions associated with bone loss and preventing bone fractures, and/or the inability to initiate de novo bone turnover and stimulate bone fracture repair.

The present invention relates to a parathyroid hormone derivative in a dimeric form of a parathyroid hormone fragment and a pharmaceutical composition for the prevention or treatment of bone diseases comprising same. When administered to an animal model, the parathyroid hormone derivative in the dimeric form of the parathyroid hormone according to the present invention significantly increases bone density and enhances osteogenesis and thus can be effectively used for the treatment and prevention of bone diseases.

The present invention relates to a parathyroid hormone derivative in a dimeric form of a parathyroid hormone fragment and a pharmaceutical composition for the prevention or treatment of bone diseases comprising same. When administered to an animal model, the parathyroid hormone derivative in the dimeric form of the parathyroid hormone according to the present invention significantly increases bone density and enhances osteogenesis and thus can be effectively used for the treatment and prevention of bone diseases.

A process for the preparation of Abaloparatide or pharmaceutically acceptable salts. Also described is pure Abaloparatide or pharmaceutically acceptable salts thereof obtained from the process for the preparation of Abaloparatide.

A process for the preparation of Abaloparatide or pharmaceutically acceptable salts. Also described is pure Abaloparatide or pharmaceutically acceptable salts thereof obtained from the process for the preparation of Abaloparatide.

The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.